Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hebei Univ. of Chinese Medicine FAK compound 9c
- Development stage
- Unknown
- Lead developer
- Hebei University of Chinese Medicine
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
Hebei Univ. of Chinese Medicine FAK compound 9c: sourced facts only. name: "In MDA-MB-231 cells, 9c demonstrated subnanomolar FAK degradation potency (DC50 = 3.6 nM), outperforming its parental inhibitor in suppressing cell proliferation, colony formation, migration and invasion." [PMID:41005113]; target: "In MDA-MB-231 cells, 9c demonstrated subnanomolar FAK degradation potency (DC50 = 3.6 nM), outperforming its parental inhibitor in suppressing cell proliferation, colony formation, migration and invasion." [PMID:41005113]; developer: "College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang 050200, PR China; Hebei International Joint Research Center for Utilization and Quality Evaluation of Traditional Chinese Medicine Resources, Hebei University of Chinese Medicine, Shijiazhuang 050200, PR China." [PMID:41005113]; modality: "Herein, we report the identification of a potent FAK-targeting PROTAC 9c via structure-guided ternary complex modeling to optimize linker geometry." [PMID:41005113]; stage: "In MDA-MB-231 cells, 9c demonstrated subnanomolar FAK degradation potency (DC50 = 3.6 nM), outperforming its parental inhibitor in suppressing cell proliferation, colony formation, migration and invasion." [PMID:41005113]
02
Targets
FAK (Focal adhesion kinase)
Beyond the preview
Go deeper on Hebei Univ. of Chinese Medicine FAK compound 9c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hebei Univ. of Chinese Medicine FAK compound 9c.